Hemanext

Executive Summary

Hemanext is a privately held medical technology company headquartered in Lexington, Massachusetts, dedicated to improving the quality and efficacy of red blood cell (RBC) transfusions. The company has developed the Hemanext ONE® system, a novel oxygen-controlled processing and storage platform designed to reduce oxidative damage to RBCs during their shelf life. By minimizing oxidative stress, the technology aims to preserve RBC function, extend storage duration, and potentially improve patient outcomes, particularly for chronically transfused populations such as those with sickle cell disease or thalassemia. Traditional blood storage methods lead to progressive deterioration known as the 'storage lesion,' which can reduce transfusion efficacy. Hemanext's approach addresses this critical unmet need, offering the potential to enhance transfusion medicine globally. The company has positioned itself as a pioneer in RBC storage innovation, with a focus on regulatory pathways and commercialization in major markets including the US and Europe.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Hemanext ONE System70% success
• Q1 2027Pivotal Clinical Trial Results Demonstrating Superiority Over Standard Storage60% success
• TBDStrategic Partnership or Licensing Agreement with a Major Blood Center or Hospital Network50% success